| Name | APX-115 free base |
| Description | APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with inhibition constants (Kis) of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4, respectively, and it effectively prevents kidney injury. |
| In vitro | In the mouse podocyte cell line, APX-115 free base (5?μM; 60?min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression. In the kidney, APX-115 free base attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes [2]. |
| In vivo | APX-115 free base treatment decreases the urinary excretion of albumin and plasma creatinine levels. APX-115 (oral gavage; 60?mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 245 mg/mL (877.07 mM), Sonication is recommended.
|
| Keywords | resistance | plasma | Nox4 | Nox3 | Nox2 | Nox1 | NOX | NADPHoxidase | NADPH Oxidase | kidney | insulin | injury | Inhibitor | inhibit | Ewha-18278 | Ewha18278 | Ewha 18278 | creatinine | APX-115 free base | APX115 free base | APX-115 | APX115 | APX 115 free base | APX 115 | albumin |
| Inhibitors Related | Metronidazole | Ketoconazole | Resveratrol | Pasiniazid | ML-090 | APX-115 | Dicoumarol | NAD+ | Apocynin | Triclosan | AKR1C1-IN-1 | Setanaxib |
| Related Compound Libraries | Glycometabolism Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |